Browsing Tag
Novo Nordisk A/S
10 posts
Eli Lilly blocked in European heart failure label push: Is the GLP‑1 race now tilting to Novo Nordisk?
Find out why Eli Lilly’s bid to expand Mounjaro’s EU label for heart failure was declined and what it means for the company’s growth strategy and competitive standing.
China just sided with Novo Nordisk—here’s why this Wegovy patent ruling matters worldwide
China’s top court just backed Novo Nordisk’s semaglutide patent—find out what this means for Wegovy and obesity drug rivals in 2026 and beyond.
Pfizer sweetens Metsera acquisition offer to secure board approval and fend off Novo Nordisk challenge
Find out how Pfizer’s amended $86.25-per-share merger with Metsera reshapes the obesity-drug race and signals Big Pharma’s shifting acquisition strategy.
Metsera picked Pfizer over Novo Nordisk — here’s what swung the $10bn deal
Pfizer secures obesity biotech Metsera for $10 billion after regulatory pushback sidelines Novo Nordisk. Find out what this means for pharma M&A now.
Merger war explodes: Pfizer drags Metsera and Novo Nordisk to court over ‘illegal’ bid
Pfizer takes legal action against Metsera and Novo Nordisk over breach of merger terms. Find out how this battle could reshape obesity drug M&A.
Will orforglipron turn Eli Lilly into the king of GLP-1s? The FDA decision that could change obesity care
Eli Lilly is stockpiling orforglipron pills ahead of FDA approval. Explore the risks, rewards, and why investors are paying close attention to this launch.
From GLP-1 to FGF21: How Novo Nordisk’s Akero Therapeutics deal signals a new era in metabolic drug dominance
Novo Nordisk’s $5.2 B Akero deal adds the FGF21 drug efruxifermin to its MASH portfolio. See how it expands the company’s metabolic dominance.
Factory shock at Clayton: Why Novo Nordisk is cutting jobs even as it expands in America’s GLP-1 boom
Find out how Novo Nordisk’s U.S. factory job cuts fit into its $4.1 billion expansion—and what it means for Wegovy, Ozempic, and GLP-1 growth in 2025.
Novo Nordisk stock rises on Wegovy STEER data: Can semaglutide cement its lead over Eli Lilly?
Novo Nordisk shares gained after STEER study showed Wegovy cut heart risks by 57% over tirzepatide. Find out why semaglutide may lead the GLP-1 race.
UnitedHealth crashes 22%—see full list of top 25 stock market losers shaking Wall Street
UnitedHealth's $130B drop led April 17's top stock market losses. Discover why healthcare, fintech, and mining stocks nosedived amid economic uncertainty.